Medicare Enrolled
Dr. Kelash Bajaj, MD
Hematology & Oncology · Odessa, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bajaj from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bajaj? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bajaj
Dr. Kelash Bajaj is a hematology & oncology in Odessa, TX, with 13 years in practice. Based on federal Medicare data, Dr. Bajaj performed 106,815 Medicare services across 4,642 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bajaj received a total of $622 from 15 pharmaceutical and/or device companies across 39 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bajaj is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice▲ Top 6% volume in TX$ $622 industry payments
Medicare Practice Summary
Medicare Utilization ↗106,815
Medicare services
Top 6% in TX for hematology & oncology
4,642
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,217 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 21,600 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 14,700 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 13,300 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 11,913 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 10,200 | $34 | $137 |
| Darbepoetin injection (Aranesp) for anemia | 7,805 | $2 | $20 |
| Paclitaxel chemotherapy injection | 7,008 | $0 | $8 |
| Dexamethasone injection (steroid) | 2,646 | $0 | $1 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,380 | $18 | $155 |
| Injection, granisetron hydrochloride, 100 mcg | 1,570 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,350 | $1 | $114 |
| Blood draw (venipuncture) | 1,333 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,269 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,263 | $10 | $64 |
| Injection, leucovorin calcium, per 50 mg | 818 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 765 | $2 | $13 |
| Office visit, established patient (30-39 min) | 562 | $94 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 497 | $21 | $157 |
| Injection, magnesium sulfate, per 500 mg | 430 | $1 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 397 | $93 | $707 |
| Reticulated (young) platelet measurement | 301 | $35 | $143 |
| Injection, zoledronic acid, 1 mg | 264 | $6 | $431 |
| Injection, carboplatin, 50 mg | 261 | $2 | $300 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 230 | $133 | $3,675 |
| Administration of chemotherapy into vein, each additional hour | 198 | $21 | $161 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 192 | $45 | $313 |
| Injection of additional new drug or substance into vein | 180 | $11 | $108 |
| Lactate dehydrogenase (enzyme) level | 163 | $6 | $31 |
| Office visit, established patient (20-29 min) | 163 | $54 | $250 |
| Administration of additional new drug or substance into vein, 1 hour or less | 147 | $48 | $344 |
| Iron level test | 144 | $6 | $27 |
| Iron binding capacity test | 144 | $8 | $35 |
| Ferritin level test (iron stores) | 143 | $13 | $60 |
| Drug injection, under skin or into muscle | 131 | $11 | $96 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 130 | $73 | $70 |
| Ct scan of chest with contrast | 120 | $44 | $821 |
| Hospital follow-up visit, low complexity | 116 | $36 | $135 |
| Injection, diphenhydramine hcl, up to 50 mg | 112 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 109 | $16 | $100 |
| CT scan of abdomen and pelvis with contrast | 104 | $158 | $1,067 |
| Irrigation of implanted venous access drug delivery device | 103 | $17 | $114 |
| Infusion into a vein for hydration, each additional hour | 91 | $9 | $75 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 79 | $24 | $145 |
| Carcinoembryonic antigen (cea) protein level | 76 | $19 | $99 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 76 | $120 | $500 |
| Microscopic examination for white blood cells with manual cell count | 75 | $4 | $22 |
| Complete blood count (CBC), automated | 75 | $6 | $34 |
| Unclassified drugs | 74 | $1 | $8 |
| PSA test (prostate cancer screening) | 72 | $18 | $94 |
| Hospital follow-up visit, moderate complexity | 71 | $54 | $247 |
| New patient office visit (45-59 min) | 68 | $116 | $565 |
| Urinalysis, manual | 61 | $3 | $15 |
| New patient office visit, complex (60-74 min) | 54 | $150 | $709 |
| Office visit, established patient, complex (40-54 min) | 54 | $137 | $496 |
| CT scan of chest, without contrast | 50 | $39 | $686 |
| Infusion, normal saline solution , 1000 cc | 50 | $2 | $19 |
| Office visit, established patient (10-19 min) | 45 | $29 | $150 |
| Red blood count automated, with additional calculations | 42 | $5 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 42 | $14 | $94 |
| Ct scan of abdomen and pelvis without contrast | 41 | $77 | $560 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 38 | $20 | $128 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 38 | $1 | $19 |
| Urinalysis with microscopic exam | 37 | $3 | $28 |
| Initial hospital admission, moderate complexity | 35 | $85 | $470 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 34 | $4 | $25 |
| New patient office visit (30-44 min) | 29 | $78 | $372 |
| Injection of drug or substance into vein | 27 | $25 | $247 |
| Drawing of blood for a medical problem | 26 | $64 | $264 |
| Administration of additional new drug or substance into vein using push technique | 24 | $42 | $289 |
| Infusion into a vein for hydration, 31-60 minutes | 22 | $25 | $256 |
| Initial hospital admission, high complexity | 19 | $125 | $694 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 16 | $55 | $348 |
| Ct scan of soft tissue of neck with contrast | 13 | $73 | $658 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
92.2% medium
6.7% routine
Industry Payment Transparency
Open Payments through 2023 ↗$622
Total received (2018-2023)
Avg $156/year across 4 years
Bottom 22% in TX for hematology & oncology
15
Companies
39
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$554 (89.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$68 (10.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023$33
2022$40
2021$35
2018$515
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$131
Novartis Pharmaceuticals Corporation
$115
Celgene Corporation
$88
AstraZeneca Pharmaceuticals LP
$56
Eisai Inc.
$35
TESARO, Inc.
$33
Takeda Pharmaceuticals U.S.A., Inc.
$33
Lilly USA, LLC
$26
Seagen Inc.
$23
Jazz Pharmaceuticals Inc.
$16
Incyte Corporation
$16
Exelixis Inc.
$13
Seattle Genetics, Inc.
$13
E.R. Squibb & Sons, L.L.C.
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 53.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Abraxane · BOSULIF · CYRAMZA · Cabometyx · Halaven · IBRANCE · ICLUSIG · IMFINZI · JADENU · JAKAFI · LYNPARZA · Lenvima · MYLOTARG · OPDIVO · Pomalyst · SANDOSTATIN LAR · TASIGNA · TUKYSA · VOTRIENT · VYXEOS · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $1 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
2
Per 100K population
1.2
County median income
$71,031
Nearest hospital
MEDICAL CENTER HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Bajaj is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Bajaj experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Bajaj performed 21,600 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bajaj receive payments from pharmaceutical companies?
Yes. Dr. Bajaj received a total of $622 from 15 companies across 39 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bajaj's costs compare to other hematology & oncologys in Odessa?
Dr. Bajaj's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bajaj) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Odessa
Browse hematology & oncologys in Odessa ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology